Deadline for application
- Educational background in biochemistry.
- Previous experience accomplishing related tasks with the job position.
- A high level of motivation and interest.
- Proficient in writing and speaking in English.
- Ability to handle varying workloads and aptitude for teamwork.
- Organized, proactive, self-motivated, and enthusiastic.
What we offer
- Incorporation in a multinational and highly collaborative team.
- An exciting and innovative research project.
- Contract details will take into account the track record of the candidate.
- Temporary position.
- Working in the mixed basic and clinical research environment of the Josep Carreras Leukaemia Research Institute.
- The stimulating environment of the Barcelona metropolitan area.
- Carrying out preclinical trials of new anti-leukemic compounds using different in vitro, ex vivo, and in vivo models and studying the signaling pathways involved in the therapeutic effect.
- To explore new technologies with diagnostic and/or prognostic potential for hematological neoplasms based on identified therapeutic targets".
Acute myeloid leukemia (AML) is a blood cancer, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with normal hematopoiesis. Although, remission rates with standard induction chemotherapy in patients with AML range from 50-85% the majority of patients will relapse and succumb to the disease within 5 years. As such, survival rates for the majority of patients with AML have not dramatically changed over the last decades and new therapeutic approaches are required for remission induction and prevention of relapse. Leukemia stem cells (LSC) are the cell population within the tumor thought to be responsible for the initiation, maintenance and relapse of the leukemia. Therefore, development of specific therapies targeted at LSCs holds hope for improvement of survival and quality of life of leukemia patients.
Please also visit our unit webpage:
Who we are?
Our mission is to carry out research into the basic, epidemiological, preventive, clinical and translational aspects of leukaemia and other hematologic malignancies.
The vision of the Josep Carreras Leukaemia Research Institute is that research will identify new therapeutic targets and enable us to develop more precise and less aggressive treatments. We aspire to understand the origin and development of leukaemia and other malignant haematological pathologies in order to be able to prevent them. We will work for a future in which all leukaemias will be curable.
The European Commission awarded the IJC the HR Excellence seal in July 2019. The IJC continues to work to maintain its policies in line with the Charter and Code principles.
The HRS4R has the main objective of ensuring that research centers of excellence implement and respect the requirements of the European Charter for Researchers and the Code of Conduct for hiring researchers (from here on referred to as the Charter and Code) within their human resources policies.
This EC initiative aims to promote training, professional development, and mobility for all European scientists. The IJC supports these values and principles, which will not only serve to strengthen its internal policies but will actively stimulate excellent research and firmly situate the organization as an institution with a stimulating working environment that favors the development of its scientists.
IJC is an equal opportunity employer. We evaluate qualified applicants without regard to race, color, religion, sex, national origin, disability, and other legally protected characteristics.
Place of presentation of the candidacies
How to apply?
To apply for this opportunity, please send your resume and a cover letter (incl. the contact details of two referees) to email@example.com in the subject of the message: REF.: TCH_RR_24.
Deadline for Applications
Please submit your application by June 15th, 2020.